BC
NTLA icon

Birchview Capital’s Intellia Therapeutics NTLA Stock Holding History

Birchview Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.78M Sell
385,900
-59,500
-13% -$833K 3.17% 4
2026
Q1 		$5.71M Buy
445,400
+130,000
+41% +$1.66M 3.25% 7
2025
Q4 		$2.84M Buy
315,400
+255,400
+426% +$3.52M 1.66% 18
2025
Q3 		$1.04M Hold
60,000
– – 0.78% 36
2025
Q2 		$563K Buy
+60,000
New +$493K 0.56% 39

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Birchview Capital's NTLA Position: Q2 2026 in Review

Birchview Capital reduced its Intellia Therapeutics (NTLA) stake by 13% in Q2 2026, selling an estimated $833K and leaving 385,900 shares worth $6.78M. The position accounts for 3.17% of the portfolio, ranked #4.

Birchview Capital first reported a position in NTLA in Q2 2025 and has held it in 5 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Birchview Capital held 385,900 shares of Intellia Therapeutics worth $6.78M as of Q2 2026.
  • Birchview Capital sold 59,500 Intellia Therapeutics shares in Q2 2026, an estimated $833K.
  • Intellia Therapeutics made up 3.17% of Birchview Capital's portfolio in Q2 2026, its #4 holding.
  • Birchview Capital first reported a position in Intellia Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.